Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FK-506--how much potential?

A W Thomson

    Immunology Today
    |January 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    FK-506 is a potent immunosuppressive drug, distinct from cyclosporin A (CsA), that inhibits interleukin-2 production and induces transplant tolerance. While highly effective, FK-506 shows severe side effects in some species, unlike CsA.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Characterization of eomesodermin and T-bet expression by allostimulated CD8<sup>+</sup> T cells of healthy volunteers and kidney transplant patients in relation to graft outcome.

    Clinical and experimental immunology·2018
    Same author

    A Tale of Two Pathways: Renewing the Promise of Anti-CD40L Blockade.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
    Same author

    Renal Allograft Survival in Nonhuman Primates Infused With Donor Antigen-Pulsed Autologous Regulatory Dendritic Cells.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
    Same author

    Impact of Human Mutant TGFβ1/Fc Protein on Memory and Regulatory T Cell Homeostasis Following Lymphodepletion in Nonhuman Primates.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
    Same author

    Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
    Same author

    In Vivo Mobilization and Functional Characterization of Nonhuman Primate Monocytic Myeloid-Derived Suppressor Cells.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
    Same journal

    Foreword.

    Immunology today·2020
    Same journal

    The origin and significance of anti-DNA antibodies.

    Immunology today·2014
    Same journal

    Mutations of class II MHC molecules.

    Immunology today·2014
    Same journal

    Antigen processing at the molecular level.

    Immunology today·2014
    Same journal

    Phenotypically and functionally distinct T-cell subsets in anti-tumor responses.

    Immunology today·2014
    Same journal

    Are MHC class II-restricted cytotoxic T lymphocytes important?

    Immunology today·2014
    See all related articles

    Area of Science:

    • Immunology
    • Pharmacology

    Background:

    • FK-506 is a novel immunosuppressive agent with properties similar to cyclosporin A (CsA).
    • Structurally distinct from CsA, FK-506 shares key functional characteristics, including immunosuppression and induction of transplant tolerance.

    Purpose of the Study:

    • To review the immunological properties of FK-506.
    • To assess the potential of FK-506 in light of CsA's established impact in laboratory and clinical settings.

    Main Methods:

    • Review of recently published findings on FK-506.
    • Comparative analysis of FK-506 and CsA properties and effects.

    Main Results:

    • FK-506 interferes with interleukin-2 (IL-2) production and other lymphokines.
    • FK-506 is more potent than CsA and can act synergistically with CsA.

    Related Experiment Videos

  • Transplantation tolerance is induced in rats with short FK-506 courses; however, severe side effects are noted in dogs and baboons.

    • Conclusions:

    • FK-506 demonstrates significant immunosuppressive potential and efficacy in inducing transplant tolerance.
    • The potent nature and synergistic effects of FK-506 offer advantages over CsA.
    • Species-specific side effects of FK-506 require careful consideration for clinical application.